Bölüm notları
ESMO 2026 brought exciting developments in lung cancer, from antibody-drug conjugates (ADCs) and targeted therapies to immunotherapy and T-cell engagers. But how much of it will actually change clinical practice?In our first full episode of (Im)Partial Response, Alex Friedlaender and José Sandoval take a critical look at the latest lung cancer data, discussing OptiTROP-Lung06, SAFFRON, OptiTROP-Lung04, PANKU-Lung01, KRAScendo-1, DeLLphi-305 and PERSEE.Survival benefits, comparators, toxicity, and clinical relevance.The main question remains: What changes in our practice?Complete opinions on…
Web sitesi: podcasters.spotify.com

